Clinical trials: psoriasis
Psoriasis
A Study of LY3361237 in Participants With Psoriasis
The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis.
- Trial name
- NCT04975295
- Testing
- LY3361237
- Where
- 7 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 21 people
- Sponsor
- Eli Lilly and Company
Psoriasis
Safety and Efficacy of Secukinumab in Mild Psoriasis
Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities.
- Trial name
- NCT03131570
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- James G. Krueger, MD, PhD
Psoriasis, Adoptive Immunotherapy
Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis
to determine the therapeutic roles of CIK cells on patients with psoriasis
- Trial name
- NCT01894373
- Testing
- Adoptive Immunotherapy, CIK
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Psoriatic Plaque
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.
- Trial name
- NCT04911751
- Testing
- KBL697
- Where
- 10 sites in United States, Australia
- Volunteers
- 80 people
- Sponsor
- KoBioLabs
Psoriasis
Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis.
- Trial name
- NCT00147329
- Testing
- MM-093
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merrimack Pharmaceuticals
Psoriasis Vulgaris
A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris
An international, multi-centre, prospective, randomised, double-blind, 4-arm, placebo controlled, parallel group study with 12 weeks once daily oral treatment in subjects with psoriasis vulgaris.
- Trial name
- NCT01116895
- Testing
- LEO 22811
- Where
- 2 sites in Canada, France
- Volunteers
- 63 people
- Sponsor
- LEO Pharma
Psoriasis
BOSTRIP: Biomarkers of Systemic Treatment Response in Psoriasis
Metabolomics of systemic psoriasis treatment
- Trial name
- Bostrip (NCT01403012)
- Testing
- Withdrawal of venous blood samples
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Technical University of Munich
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Psoriasis
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-38518168 in participants with moderate to severe plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease…
- Trial name
- NCT02295865
- Testing
- JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg
- Where
- 13 sites in United States, Poland
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC
PsA (Psoriatic Arthritis)
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.
- Trial name
- D2570-204 (NCT07315061)
- Testing
- D-2570
- Where
- China
- Volunteers
- 222 people
- Sponsor
- InventisBio Co., Ltd
Psoriasis, Psoriatic Arthritis
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
- Conditions
- Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
- Trial name
- NCT01988103
- Testing
- Apremilast
- Where
- 56 sites in Japan
- Volunteers
- 254 people
- Sponsor
- Amgen
Psoriatic Arthritis
to Translate and Validate the TOPAS TORONTO PSORIATIC SCREENING QUESTIONNAIRE)Into Spanish
TO TRANSALETE AND VALIDATE DE TORONTO PSORIATIC ARTHRITIS SECREENING QUESTIONAIRE INTO SPANISH
- Trial name
- spanishTopas (NCT01891903)
- Where
- Colombia
- Volunteers
- 60 people
- Sponsor
- Reumatologia Integral LTDA
Psoriasis
A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis
Psoriasis is a common, chronic skin disease for which only remissive, as opposed to curative, treatments are available. Traditional Chinese medicine is one of the most frequently chosen alternative therapies in China and Taiwan…
- Trial name
- NCT01901705
- Testing
- Indigo naturalis ointment
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- China Medical University Hospital
Psoriasis
International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis
BCD-085-2 is a next step in clinical investigation of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-2 trial patients with moderate to severe plaque psoriasis, in whom poor response to previous…
- Trial name
- NCT02762994
- Testing
- BCD-085
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biocad
Arthritis, Psoriatic, Psoriasis
A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
This is a placebo controlled study evaluating the role of fludarabine (a nucleoside analog targeting both resting and proliferating lymphocytes) in the treatment of moderate to severe psoriotic arthritis.
- Trial name
- NCT00001422
- Testing
- fludarabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
- Trial name
- POETYK-PsO-Ped (NCT06979453)
- Testing
- Deucravacitinib
- Where
- 133 sites in United States, Argentina and 14 more
- Volunteers
- 366 people
- Sponsor
- Bristol-Myers Squibb
Chronic Plaque-type Psoriasis
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body…
- Trial name
- NCT00941031
- Testing
- AIN457, AIN457A
- Where
- 62 sites in United States, France and 5 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Nailfold Capillaroscopic Changes in Psoriasis
The goal of this observational study is to evaluate nailfold capillaroscopic changes in patients with psoriasis and to assess their correlation with disease severity.
- Trial name
- NCT07693595
- Testing
- Nailfold Capillaroscopy
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Al-Azhar University
Psoriasis
Taltz in Combination With Enstilar for Psoriasis
Enstilar in combination with Taltz for plaque psoriasis.
- Trial name
- NCT04372277
- Testing
- Enstilar
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Insulin Sensitivity, Metabolism Disorder
Insulin Sensitivity, Glucose - and Fat Metabolism in Patients With Psoriasis
The pathophysiological mechanisms explaining the association between psoriasis and type 2 diabetes are largely unknown but it has been hypothesized that systemic inflammation found in both psoriasis and type 2 diabetes might play…
- Trial name
- NCT02978001
- Testing
- Stabile Isotope tracers
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.